PURE BIOSCIENCE, INC. financial data

Symbol
PURE on OTC
Location
El Cajon, CA
Fiscal year end
31 July
Latest financial report
10-Q - Q3 2025 - 15 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 65% % -48%
Quick Ratio 9.8% % 1.8%
Debt-to-equity -120% % 13%
Return On Equity 44% % -67%
Return On Assets -224% % 36%
Operating Margin -86% % 50%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 111,886,473 shares 0.03%
Common Stock, Shares, Outstanding 111,886,473 shares 0.03%
Entity Public Float $4,674,000 USD -36%
Common Stock, Value, Issued $1,119,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 111,886,473 shares 0.03%
Weighted Average Number of Shares Outstanding, Diluted 111,886,473 shares 0.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,350,000 USD 31%
Revenue from Contract with Customer, Excluding Assessed Tax $2,354,000 USD 31%
Research and Development Expense $331,000 USD 13%
Operating Income (Loss) $2,024,000 USD 35%
Nonoperating Income (Expense) $150,000 USD 24%
Net Income (Loss) Attributable to Parent $2,174,000 USD 34%
Earnings Per Share, Basic -0.01 USD/shares 67%
Earnings Per Share, Diluted -0.01 USD/shares 67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $434,000 USD 25%
Accounts Receivable, after Allowance for Credit Loss, Current $389,000 USD 4.9%
Inventory, Net $237,000 USD 229%
Assets, Current $1,176,000 USD 29%
Property, Plant and Equipment, Net $10,000 USD -23%
Assets $1,186,000 USD 28%
Accounts Payable, Current $879,000 USD 22%
Accrued Liabilities, Current $176,000 USD -8.8%
Liabilities, Current $3,159,000 USD 247%
Liabilities $6,732,000 USD 52%
Retained Earnings (Accumulated Deficit) $139,458,000 USD -1.6%
Stockholders' Equity Attributable to Parent $5,546,000 USD -59%
Liabilities and Equity $1,186,000 USD 28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $250,000 USD 50%
Net Cash Provided by (Used in) Financing Activities $350,000 USD -30%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 111,886,473 shares 0.03%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $100,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $509,000 USD 21%
Deferred Tax Assets, Valuation Allowance $29,290,000 USD -0.1%
Deferred Tax Assets, Gross $29,290,000 USD -0.1%
Depreciation $1,000 USD
Property, Plant and Equipment, Gross $1,615,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $26,840,000 USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $132,793,000 USD 0.09%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $34,000 USD -40%
Interest Expense $111,000 USD 1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%